In 2014, a meta-analysis by Cortazar et al. [17] including 11,955 patients found a stronger association between pCR and long-term outcomes in patients with TNBCs (RFS: HR = 0.24, 95% CI [0.18–0.33]) and in those with HER2-positive hormone receptor negative BC (RFS: HR = 0.15, 95% CI [0.09–0.27]); whereas the association was less marked in HER2-positive hormone receptor positive BC (RFS: HR = 0.58, 95% CI [0.42–0.82]) and luminal BC (RFS: HR = 0.49, 95% CI [0.33–0.71]). Here, NR4A1 is linked to breast cancer.